Tianda Group established Tianda Pharmaceuticals (Australia) Pty Ltd.

Hansom Holdings Ltd renamed to Yunnan Enterprises Holdings Ltd, primarily engaging in trading and investing in companies.

Hansom Holdings Ltd listed in the Hong Kong Stock Exchange, Stock Code : 00455.HK.

Tianda Group and Yunnan Enterprises Holdings Ltd conducted asset swap, which included, among others, injecting Tianda Group’s 60% stakes in Zhuhai S.E.Z. Chengcheng Printing Co Ltd into Yunnan Enterprises Holdings Ltd, while Yunnan Enterprises Holdings Ltd selling Zhuhai lot to Tianda Group.

Tianda Group injected capital to Yunnan Enterprises Holdings Ltd in form of a lot in Zhuhai, China and became the controlling shareholder with a total interest of 50.86%.

Tianda Group acquired 9.35% interest of Yunnan Enterprises Holdings Ltd for the first time.

Yunnan Enterprises Holdings Ltd increased shareholdings of Yunnan Mensheng Pharmaceutical Ltd to 55%.

Yunnan Enterprises Holdings Ltd acquired 49% interest of Yunnan Mensheng Pharmaceutical Ltd.

Tianda Group Limited established the Zhuhai R&D and Production Base through acquisition, which was later renamed as Tianda Pharmaceuticals (Zhuhai) Limited.

Tianda Group established Tianda Pharmaceuticals (Shengzhen) Limited, which was later renamed as Tianda Pharmaceuticals (China) Limited.

Tianda Group established Tianda Pharmaceuticals Limited.

In Feb, Tianda Pharmaceuticals Limited, Tianda Chinese Medicine Limited, TDMall (Group) Limited, and Tianda Chinese Medicine Institute together with national level Chinese medicine experts, jointly developed “Anti-epidemic formula 1”, carried out free Chinese medicine consultation and herbal medicines in order to support Guangdong, Hong Kong, Macau, Hubei Province and the nation ’s anti-coronavirus action.

TDMall (Causeway Bay), the first TDMall of Hong Kong and the second in the Guangdong-Hong Kong-Macao Greater Bay Area, was grandly opened on 24 Feb.

In April, the Anti- Epidemic Formula 1 granules entered into Australian register of therapeutic goods and passed a SGS’s testing with test results showing that the product meets the required standards of the relevant proprietary Chinese medicine in Hong Kong.

TDMall opened its first flagship clinic – Zhuhai TDMall in the Guangdong-Hong Kong-Macao Greater Bay Area on 2 May.

Zhuhai TDMall Ltd and TDMall Pty Ltd were established.

Acquired Zhuhai City Tonghui Pharmaceutical Co. Ltd, renamed as Zhuhai Tianda Processed Chinese Herbal Medicine Limited, to expand its TCM business (GMP certification attained).

Tianda Chinese Medicine Limited, TDMall (Group) Limited, and Tianda Chinese Medicine Institute were established.

TDMall (China) Ltd and TDMall (Hong Kong) Limited were established.

The Company acquired Zhuhai Renheng Pharmaceutical Ltd to further expand in the Chinese medicine realm. It was then renamed Tianda Chinese Medicine (China) Limited.

SIIC Medical Science and Technology (Group) Ltd became the second largest shareholder of the Company with about 13% of its stake. Later, the Company invested in ASLAN, a R&D Specialist of Oncology Therapies, and tapped into the high-end medical area.

The Company acquired Australian-based Cynergy Health's business.

Tianda Pharmaceuticals Limited renamed as Tianda Pharmaceuticals (Hong Kong) Limited.

Tianda Group and Tianda Holdings Limited conducted asset swap again, aiming to consolidate all pharmaceutical business to Tianda Holdings Limited and moving all non-pharmaceutical business to Tianda Group. Tianda Holdings Limited then formally changed name to Tianda Pharmaceuticals Limited.

Yunnan Enterprises Holdings Ltd changed its name to Tianda Holdings Limited.

On February 5, TDMall, the subsidiary brand of Tianda Pharmaceuticals Limited won the 2023 Hong Kong Emerging Service Brand Awards.

On May 16, Tianda Pharmaceuticals (Yunnan) Co., Ltd has been granted the drug registration approval of “Nicorandil for Injection” by the National Medical Products Administration of the People’s Republic of China.

Tianda Pharmaceutical Technology (Zhuhai) Co., Ltd., a wholly-owned subsidiary of the Company, has been granted the drug registration approval of Ibuprofen suspension (the “Product”) by the National Medical Products Administration of the People’s Republic of China.

29 March 2023, TDMall (Group) Limited, a subsidiary of Tianda Pharmaceuticals Limited (listed on the Hong Kong Stock Exchange, stock code: 0455.HK), has invested in and established the modern Traditional Chinese Medicine (TCM) clinic chain “TDMall”, dedicated to providing high-quality TCM healthcare services.

On August 1st, Yunyu Bio-pharmaceutical Co., Ltd., a wholly-owned subsidiary of Tianda Pharmaceutical Co., Ltd., acquired Yunnan Li Nuo Biotechnology Co., Ltd.

TDMall (Group) Limited launched its Cloud-based Global Anti-epidemic Chinese Medicine Platform on “TDMall on Cloud” App in April, providing comprehensive Chinese medicine services from prevention, recovery, rehabilitation worldwide.

Zhuhai R&D and production base moved to the Jinwan District of Zhuhai in May.

The “TDMall on Cloud” App is connected to Guangdong’s Internet medical service monitoring platform on 10 May.

TDMall was awarded ISO 9001:2015 Quality Management System Certification and Qualicert International Service Quality Certification by SGS, and became the first Chinese medicine clinic in China to receive both recognition.

Tianda Pharmaceuticals obtained approval from National Medical Products Administration (NMPA) as marketing authorization holder (MAH) of Xiaoer Qingre Zhike granules, acquiring the whole technology ownership and all the intellectual rights of the product on 9 Nov.

TDMall(Sydney), the first TDMall of Australia and the third in the world grandly opened on 14 Mar.

TDMall (Tsim Sha Tsui), the fourth TDMall worldwide and second TDMall in Hong Kong, has been opened on 9 Sep.